Positive results from the first clinical study with CS1

Cereno Scientific’s first clinical study with CS1 has been concluded, with positive results regarding safety, pharmacokinetic properties and effect on biomarker for the risk of thrombosis.

Read more



Cereno investor presentation 5.55 pm in Göteborg ’’Companies of the future’’ in collaboration with Redeye and GU Ventures. 2 May 2018

Q1 report 24 May 2018

Cereno presentation, 2.05 pm at the Redeye Growth Day, Scandic Haymarket Stockholm 4 June 2018

Annual General Meeting 13 June 2018

More about us...

We are proud supporters of World Thrombosis Day. Read more here.